{
    "nctId": "NCT00304096",
    "briefTitle": "Vaccine Therapy in Treating Patients With Stage III or Stage IV Breast Cancer",
    "officialTitle": "Evaluation of the Safety and Immunogenicity of Vaccination With Multiple Synthetic Peptides in Participants With Advanced Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 12,
    "primaryOutcomeMeasure": "The Number of Participants Who Experienced Dose-limiting Adverse Events",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed adenocarcinoma of the breast\n\n  * Stage III or IV disease\n  * Primary or recurrent disease\n  * Invasive lobular carcinoma allowed\n* HLA-A1, -A2, -A3, or -A31 positive\n* Underwent and recovered from prior primary therapy\n\n  * Patients with no clinical or radiological evidence of disease who had a previous diagnosis of stage III or IV breast cancer must have undergone prior antineoplastic therapy including, but not limited to, surgery, chemotherapy, and radiotherapy within the past 36 months\n* Must have at least one undissected axillary and/or inguinal lymph node basin\n* No history of brain metastases\n* Hormone receptor status\n\n  * Estrogen receptor-positive or -negative tumor\n\nPATIENT CHARACTERISTICS:\n\n* ECOG performance status of 0 or 1\n* Body weight \\> 110 lbs (without clothes)\n* Male or female\n* Menopausal status not specified\n* Absolute neutrophil count \\> 1000/mm\\^3\n* Platelet count \\> 100,000/mm\\^3\n* Hemoglobin \\> 9 g/dL\n* Hemoglobin A1c \\< 7%\n* AST and ALT \u2264 2.5 x upper limit of normal (ULN)\n* Bilirubin \u2264 2.5 x ULN\n* Alkaline phosphatase \u2264 2.5 x ULN\n* Creatinine \u2264 1.5 x ULN\n* HIV negative\n* Hepatitis C negative\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* No known or suspected allergies to any component of the vaccine\n* No active infection requiring antibiotics\n* No New York Heart Association class III or IV heart disease\n* No autoimmune disorders requiring cytotoxic or immunosuppressive therapy or autoimmune disorders with visceral involvement, except the following:\n\n  * Laboratory evidence of autoimmune disease (e.g., positive ANA titer) without symptoms\n  * Clinical evidence of vitiligo\n  * Other forms of depigmenting illness\n  * Mild arthritis requiring nonsteroidal antiinflammatory drugs\n* No medical contraindication or potential problem that would preclude study participation\n\nPRIOR CONCURRENT THERAPY:\n\n* More than 4 weeks since prior surgery\n* More than 4 weeks since prior and no concurrent chemotherapy and radiotherapy\n* More than 4 weeks since prior and no concurrent allergy desensitization injections\n* More than 4 weeks since prior parenteral, oral, or inhaled corticosteroids\n\n  * No concurrent inhaled steroids (e.g., Advair\u00ae or triamcinolone acetonide)\n  * Prior or concurrent topical corticosteroids allowed\n* More than 4 weeks since prior and no concurrent growth factors (e.g., epoetin alfa, darbepoetin alfa, or pegfilgrastim)\n* More than 4 weeks since prior and no concurrent other investigational medication\n* More than 4 weeks since prior and no concurrent other agents with putative immunomodulating activity except for non-steroidal anti-inflammatory agents\n* Prior and concurrent hormonal therapy (e.g., tamoxifen, raloxifene, toremifene, fulvestrant, letrozole, anastrozole, or exemestane) allowed\n* No prior vaccination with any synthetic peptides in this protocol\n\n  * Vaccines for infectious disease (e.g., influenza) allowed, provided they are administered \u2265 2 weeks prior to or \u2265 2 weeks after study vaccine\n* Short term therapy for acute conditions not related to breast cancer allowed\n* No concurrent illegal drugs",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}